Cinfa Biotech reports positive top-line clinical trial results of B12019 to treat neutropenia

Spanish biosimilars company Cinfa Biotech has reported positive top-line clinical trial results of B12019, a biosimilar version of Neulasta (pegfilgrastim), to treat chemotherapy-induced neutropenia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news